IL-22 produced by type 3 innate lymphoid cells (ILC3s) reduces the mortality of type 2 diabetes mellitus (T2DM) mice infected with Mycobacterium tuberculosis

Deepak Tripathi; Rajesh Kumar Radhakrishnan; Ramya Sivangala Thandi; Padmaja Paidipally; Kamakshi Prudhula Devalraju; Venkata Sanjeev Kumar Neela; Madeline Kay McAllister; Buka Samten; Vijaya Lakshmi Valluri; Ramakrishna Vankayalapati

doi:10.1371/journal.ppat.1008140

. 2019 Dec 6;15(12):e1008140. doi: 10.1371/journal.ppat.1008140

IL-22 produced by type 3 innate lymphoid cells (ILC3s) reduces the mortality of type 2 diabetes mellitus (T2DM) mice infected with Mycobacterium tuberculosis

Deepak Tripathi ¹, Rajesh Kumar Radhakrishnan ¹, Ramya Sivangala Thandi ¹, Padmaja Paidipally ¹, Kamakshi Prudhula Devalraju ², Venkata Sanjeev Kumar Neela ², Madeline Kay McAllister ¹, Buka Samten ¹, Vijaya Lakshmi Valluri ², Ramakrishna Vankayalapati ^1,^*

Editor: David M Lewinsohn³

PMCID: PMC6919622 PMID: 31809521

Abstract

Previously, we found that pathological immune responses enhance the mortality rate of Mycobacterium tuberculosis (Mtb)-infected mice with type 2 diabetes mellitus (T2DM). In the current study, we evaluated the role of the cytokine IL-22 (known to play a protective role in bacterial infections) and type 3 innate lymphoid cells (ILC3s) in regulating inflammation and mortality in Mtb-infected T2DM mice. IL-22 levels were significantly lower in Mtb-infected T2DM mice than in nondiabetic Mtb-infected mice. Similarly, serum IL-22 levels were significantly lower in tuberculosis (TB) patients with T2DM than in TB patients without T2DM. ILC3s were an important source of IL-22 in mice infected with Mtb, and recombinant IL-22 treatment or adoptive transfer of ILC3s prolonged the survival of Mtb-infected T2DM mice. Recombinant IL-22 treatment reduced serum insulin levels and improved lipid metabolism. Recombinant IL-22 treatment or ILC3 transfer prevented neutrophil accumulation near alveoli, inhibited neutrophil elastase 2 (ELA2) production and prevented epithelial cell damage, identifying a novel mechanism for IL-22 and ILC3-mediated inhibition of inflammation in T2DM mice infected with an intracellular pathogen. Our findings suggest that the IL-22 pathway may be a novel target for therapeutic intervention in T2DM patients with active TB disease.

Author summary

Type 2 diabetes mellitus (T2DM) during Mtb-infection leads to a pathological immune response in the lung. IL-22 plays an important role in the host defense against bacteria at mucosal surfaces, maintaining tissue barrier integrity by protecting epithelial cells and reducing chronic inflammation. In the current study, we investigated the role of IL-22 during Mtb infection in human samples and T2DM mice. We found that plasma IL-22 levels were significantly lower in Mtb-infected T2DM mice than in Mtb-infected nondiabetic mice. Similarly, IL-22 levels were significantly lower in TB patients with T2DM than in TB patients without T2DM. Type 3 innate lymphoid cells (ILC3s) were an important source of IL-22 in the lungs of Mtb-infected mice. Mtb-infected T2DM mouse lungs had fewer IL-22+ ILC3s than did the lungs of Mtb-infected non-T2DM mice. Recombinant IL-22 and IL-22 producing ILC3s reduced the bacterial burden, lung epithelial cell damage, insulin level and lipid metabolites and prolonged the survival of Mtb-infected T2DM mice. Our findings demonstrate that IL-22 produced by ILC3s is essential to inhibit excess inflammation and epithelial cell damage in T2DM mice infected with Mtb. Further understanding of these mechanisms and human studies can help to treat TB patients with T2DM.

Introduction

Type 2 diabetes mellitus (T2DM) individuals are susceptible to various bacterial, viral and protozoan infections, including Mycobacterium tuberculosis (Mtb) [1–3]. Enhanced susceptibility to Mtb infection in patients with T2DM has been attributed to several factors, such as direct effects related to hyperglycemia and insulin resistance and indirect effects related to macrophage and lymphocyte function [4–7]. T2DM significantly increases the risk of developing active tuberculosis (TB) disease in latent tuberculosis infection (LTBI)+ individuals [8]. TB patients with T2DM are unresponsive to TB therapy which leads to treatment failure, relapse, and death [9,10]. Abnormal physiological pulmonary functions of T2DM individuals delay Mtb clearance [11]. Patients with chronic T2DM show impaired innate and adaptive immune responses to Mtb antigens [7,12,13].

Among the various immune cells, macrophages play an important role in defense against Mtb infection by producing cytokine and chemokines and promoting granuloma formation to prevent Mtb dissemination [14,15]. Monocytes from T2DM individuals express an increased level of CCR2, which influences the migratory capacity of monocytes [16]. TB patients with T2DM exhibit an increased frequency of hypodense alveolar macrophages, which correlate with disease severity [17]. Neutrophilic inflammation is a central feature of TB patients with T2DM and is associated with macrovascular complications [4]. Individuals with T2DM and TB exhibit an increased level of systemic β-defensin, and excess production of antimicrobial peptides such as cathelicidin (LL37) and human beta defensin- 2 which can initiate tissue damage [18]. T2DM also influences adaptive immunity against Mtb infection [13], and patients with T2DM-TB exhibit elevated frequencies of IFN-γ, IL-2, TNF-α and IL-17 producing CD4+ cells [7,19]. Previously, we found that natural killer (NK) and CD11c+ cell interactions can increase IL-6 production, which in turn drives the pathological immune response and mortality associated with Mtb infection in diabetic mice [19]. However, the various immune cell populations and factors that can inhibit pathological immune responses in TB patients with T2DM are not known.

Innate lymphoid cells (ILCs) play an important role in controlling infections and maintaining homeostasis by regulating excess inflammation [20–22]. These cells mirror the phenotypes and functions of T cells but do not have antigen-specificity [20,23]. ILCs are divided into three groups based on the expression of transcription factors, cytokines production and cytotoxic function [21]. ILC1s express T-bet and produce interferon-γ (IFN-γ). ILC2s express higher levels of GATA-3 and produce IL-5, IL-13 and amphiregulin. ILC3s express the transcription factor RORγt and produce the Th17 cytokines IL-17 and IL-22. ILC3s accumulate rapidly in the lung after Mtb infection and mice that lack ILC3s are unable to control Mtb growth [24]. IL-17 and IL-22 are produced by ILC3s control the early stage of Mtb infection [24].

The Th17 cytokine IL-22 inhibits the intracellular growth of Mtb [25], provide protection during virulent Mtb infection [26,27] and regulates vaccine-induced protective immunity against challenge with Mtb [28]. IL-22 contributes to tissue healing processes and promotes innate immune responses to limit damage during infections [29,30]. IL-22 is primarily produced by innate lymphoid cells (ILCs), NK cells, macrophages, NKTs, activated Th1, Th17, Th22 and γδ T cells [26,31]. IL-22 binds to its heterodimeric receptor complex consisting of IL-22R1 and IL-10R2 to activate the JAK-STAT signaling pathways [32,33]. IL-22R is expressed by epithelial cells, dermal cells, liver, pancreas, and kidney cells [33].

Serum IL-22 levels are significantly reduced in TB patients with T2DM compared with TB patients without T2DM [1,34], however limited information is available regarding the role of IL-22 during TB-diabetes comorbidity [35]. In a high-fat diet mouse model of T2DM, the impaired induction of IL-22 by CD4+ cells enhances susceptibility to infection by the intestinal pathogen Citrobacter rodentium [36] The intraperitoneal administration of IL‐22 significantly improve host mucosal defense and hyperglycemia and dyslipidemia in T2DM mice [36].

IL‐22 has been shown to protect insulin-producing β-cells by suppressing endoplasmic reticulum stress and inflammation, restoring glucose homeostasis, preserving the integrity of the gut mucosal barrier, and improving endotoxemia and chronic inflammation in an obesity-induced T2DM mouse model [36,37]. It is not known whether IL-22 and ILC3 cells can regulate pathological immune responses during Mtb infection in hosts with T2DM. In this study, we determined the contribution of ILC3 cells and IL-22 in reducing T2DM-induced pathology and survival of Mtb-infected T2DM mice. We also determined the IL-22-dependent mechanisms that reduce pathology in the lungs of T2DM mice infected with Mtb.

Methods

Patient population

Blood samples were obtained from 32 patients with active TB and 14 patients with both active TB and T2DM. All included patients were newly diagnosed and had culture proven active pulmonary TB. Patients with any prior episode of TB treatment, pregnancy, seropositive for HIV or taking immunosuppressive drug were excluded from the study. Demographic details of the patients are provided in S1 Table.

Collection of blood sample and plasma separation

Whole blood samples were collected by venipuncture in a citrate-treated tubes. Plasma samples were immediately separated by refrigerated centrifugation for 15 minutes at 2,000 x g. The cell free plasma from the blood samples was stored at -70°C.

Animals

Specific-pathogen-free 6-week-old female wild-type C57BL/6 mice were purchased from Jackson Laboratory and housed at the animal facility of the University of Texas Health Science Center at Tyler. All mice were maintained and used in accordance with approved protocol of The Institutional Animal Care and Use Committee of the University of Texas Health Science Center at Tyler. Sample sizes were chosen following empirical statistical power analysis based on previous published studies [19]. For survival studies 10 mice/group were used, while for immune-phenotyping and histological analysis 5 mice/group were used. All mice were maintained on a standard rodent chow diet (LabDiet, catalog number 5053, St. Louis, MO, USA: 4.07 kcal/gm) during the experiment. After Mtb infection all mice were housed at five animals per cage in high-efficiency particulate air (HEPA) filtered racks in certified animal biosafety level 3 (ABSL-3) laboratories. The weights and blood glucose levels of mice were recorded weekly.

Ethics statement

All human studies were approved by the Institutional Review Board of the Bhagwan Mahavir Medical Research Centre, and informed written consent was obtained from all participants. All human subjects involved in our study were adults. All animal studies were approved by the Institutional Animal Care and Use Committee of the University of Texas Health Science Center at Tyler (Protocol #587). All animal procedures involving the care and use of mice were undertaken in accordance with the guidelines of the NIH/OLAW (Office of Laboratory Animal Welfare).

Induction of type 2 diabetes

Type 2 diabetes was induced by the combined administration of streptozotocin (STZ) and nicotinamide (NA). STZ was dissolved in a 50 mM citric acid buffer, and 180 mg/kg body weight was administered intraperitoneally thrice at 10 day intervals. NA was dissolved in saline, and 60 mg/kg body weight was administered intraperitoneally 15 minutes before the administration of STZ. Blood glucose was measured using a glucometer at weekly intervals for up to 8 months. Mice were considered diabetic if their blood glucose was >250 mg/dl. Blood glucose levels of the control mice remained between 80 and 100 mg/dl [19].

Aerosol infection of mice with Mtb H37Rv

Before infecting mice with Mtb H37Rv, bacteria were grown in 7H9 liquid medium to mid-log phase and then frozen in aliquots at -70°C. Bacterial counts were determined by plating on 7H10 agar plates supplemented with oleic albumin dextrose catalase (OADC). For infection, bacterial stocks were diluted in 10 ml of normal saline to 0.5 x 10⁶ colony-forming units (CFU)/ml, 1 x 10⁶ CFU/ml, 2 x 10⁶ CFU/ml and 4 x 10⁶ CFU/ml and placed in a nebulizer in an aerosol exposure chamber custom made by the University of Wisconsin. In preliminary studies, groups of three mice were exposed to the aerosol at each concentration for 15 minutes. After 24 hours, the mice were euthanized, and homogenized whole lungs were plated on 7H10 agar plates supplemented with OADC. Colony forming units were determined after 22 days of incubation at 37°C with 5% CO₂. For further studies, we selected the concentration that deposited ~100 bacteria in the lung during aerosol infection.

Lung cell preparation

Lungs were harvested from the control or T2DM mice at the indicated time points after Mtb challenge and were placed into 30-mm dishes containing 2 ml of Hank's balanced salt solution (HBSS). The tissues were minced with scissors into pieces no larger than 2–3 mm, and the fluid was discharged onto a 70-μm filter (BD Biosciences, San Jose, CA) that had been prewetted with 1 ml of PBS containing 0.5% bovine serum albumin (BSA, Sigma-Aldrich) suspended over a 50-ml conical tube. The syringe plunger was then used to gently disrupt the lung tissue before washing the filter with 2 ml of cold PBS/0.5% BSA.

Recombinant IL-22 treatment

In some experiments, mice were treated with recombinant IL-22. One month after the induction of T2DM, mice were challenged with aerosolized Mtb. Five months p.i., one group of mice were intravenously treated with a single dose of recombinant IL-22 (100 ng/kg body weight) and another group of mice was treated with recombinant IL-22 (100 ng/kg body weight) (BioLegend) or PBS twice a week.

Isolation of lung epithelial cells

Lungs from Mtb-infected mice were mechanically homogenized and filtered through a 70-μm cell strainer. Lung epithelial cells were isolated by negative selection with magnetic beads conjugated to an antibody cocktail (Stem Cell Inc.), and negatively selected cells were >96% EpCAM⁺, as measured by flow cytometry.

Isolation of type 3 innate lymphoid 3 cells (ILC3s) and adoptive transfer

ILC3 populations, lymphoid tissue inducer (LTi) (Lin-CD127+NK1.1-NKp46-CCR6+) and NCR+ (Lin-CD127+NK1.1-NKp46+CCR6-) cells, were sorted from the pooled spleen, lung, intestine and peripheral lymph node cells of CD45.1 C57BL/6 mice by using a FACSAria cytometer (BD Biosciences). The purity of the flow cytometry-sorted cell population was greater than 98%. Flow-sorted LTi or NCR+ cells were adoptively transferred (0.5 X 10⁵) through tail vein injection to CD45.2 Mtb-infected T2DM mice.

In vivo intestinal barrier function assay

Control or Mtb-infected T2DM mice were treated with PBS or recombinant IL-22 and gavaged with 10 mg/ml 10 kDa FITC-dextran (40 mg/100 g body weight) (Sigma Aldrich). Twelve hours later, whole blood was collected, and serum was separated by centrifugation at 3,000 rpm for 10 minutes. Serum was then diluted 4-fold in PBS and added to a 96-well black wall microplate in duplicate for measurement of fluorescence intensity using a fluorometer (BioTek) [38].

Antibodies and other reagents

For flow cytometry, we used PE anti-IL-22 (eBioscience), FITC anti-lineage (Biolegend), PE anti-NKp46 (Biolegend), PE cy7 anti-CCR7 (Biolegend), PE cy7 anti-CD127 (Biolegend), Brilliant violet 510 anti-Thy1.1, PE anti-ROR-γ (BD biosciences), PE anti-GATA-3 (Biolegend), Brilliant violet 640 anti-ICOS (Biolegend), APC anti-CD4 (Biolegend), APC anti-γδ T cells (eBioscience), PerCP5.5 anti-NK1.1 (Biolegend) and PE anti-CD8 (Biolegend). Streptozotocin and nicotinamide were obtained from Sigma Chemicals. Anti-EpCAM, anti-Ly6G, anti-F4/80, anti-CD11C and secondary antibodies (goat anti-hamster IgG-Alexa 568, donkey anti-rat-Alexa 488, goat anti-rabbit-Alexa 647) and DAPI were obtained from life technologies for confocal microscopy. γ-Irradiated Mtb H37Rv (γ-Mtb) was obtained from BEI Resources. Highly purified mouse recombinant IL-22 with a specific activity of 1 × 10⁸ units/mg was purchased from Biolegend, USA (Bedford, MA).

Measurement of serum insulin concentrations

After 5 months of Mtb infection T2DM mice were given PBS or treated with recombinant IL-22. After one month of treatment, serum insulin levels were measured using a Mercodia Ultrasensitive Insulin ELISA Kit (Mercodia AB Uppsala, Sweden).

Measurement of serum lipid profiles

Mtb infected T2DM mice were administered PBS or treated with recombinant IL-22 or ILC3s. After one month, serum free fatty acid (FFA), cholesterol and triglyceride levels were measured using either a fluorometric or a colorimetric assay (Cayman Chemicals, USA) according to the manufacturer’s instructions.

Flow cytometry and intracellular staining

After the mice were euthanized, their lungs were perfused through the right ventricle with 5 ml of PBS. Lungs were mechanically homogenized and filtered through a 70-μm cell strainer. The red blood cells were lysed using BD Pharm Lyse (BD Biosciences). Surface staining for leukocyte populations was performed. For IL-22 and IFN-γ intracellular staining, cells were suspended at 10⁶ cells/ml in RPMI 1640 containing 10% FBS and brefeldin A (5 μg/ml) in 24-well culture plates and stimulated with PMA (1 μg/ml) and ionomycin (1 μg/ml), after which all cells were incubated for another 4 hours at 37°C to allow for the intracellular accumulation of cytokines. Cells were permeabilized with 0.1% saponin and stained for intracellular IL-22 and IFN-γ. The cells were washed and resuspended in FACS buffer. Cells were analyzed by flow cytometry using a FACS Calibur flow cytometer.

Gating strategies

Type 1 innate lymphoid cells (ILCs1) were identified as CD45+CD127+lin-NKp46+NK1.1+ cells. Type 2 innate lymphoid cells (ILCs2) were gated as CD45+CD127+lin-Rorγt-Sca1+ cells. In Type 3 innate lymphoid cells, tissue lymphoid inducer (LTi) cells were gated as CD45+CD127+lin-NK1.1-Rorγt+NKp46-CCR6+ cells and NCR+ cells were gated as CD45+CD127+lin-NK1.1-Rorγt+NKp46+CCR6- cells.

Real-time PCR for the quantification of cytokine mRNA

Total RNA was extracted from lung epithelial cells as described previously [39]. Total RNA was reverse transcribed using the Cloned AMV First-Strand cDNA Synthesis Kit (Life Technologies). Real-time PCR was performed using the QuantiTect SYBR Green PCR Kit (Qiagen) in a sealed 96-well microtiter plate (Applied Biosystems) on a spectrofluorometric thermal cycler (7700 PRISM; Applied Biosystems). PCRs were performed in triplicate as follows: 95°C for 10 min and 45 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. All samples were normalized to the amount of β-actin/GAPDH transcript present in each sample. The primers used in the study are provided in S2 Table.

Histology and immunohistochemistry

At each time point, mice were euthanized, and the harvested lungs were placed in 10% neutral buffered formalin (Statlab, McKinney, TX, USA) for 48 hours to inactivate the infectious agent. Paraffin-embedded blocks were cut into 5 μm-thick sections. For morphometric lesion analyses, the lung sections were stained with hematoxylin and eosin (H&E) and examined in a blinded manner to assess the necrotic lesions. A semi quantitative analysis was performed using a score from 0 (no inflammation) to 4 (severe inflammation) for each of the following criteria: alveolar wall inflammation; alveoli destruction; leukocyte infiltration and perivascular inflammation. Two investigators, independently assessed the immunohistochemical readouts using morphometric analyses.

Confocal microscopy

Confocal microscopy was performed to colocalize IL-22R1 expressing EpCAM positive cells, Ly6G+, F4/80 and CD11c+ cells in the above lung sections. Nonspecific binding was blocked with 1% goat serum in PBS for 30 minutes. The slides were incubated at 4°C overnight with monoclonal hamster monoclonal anti-CD11c (Abcam), rabbit polyclonal anti-EpCAM (Abcam) and rat monoclonal anti-IL-22R1 (R&D) antibodies. Subsequently, the slides were washed thoroughly using 1X PBS. Then, cells were stained with their respective secondary antibodies (goat anti-hamster IgG-Alexa 568, goat anti-rabbit-Alexa 647 and donkey anti-rat- Alexa 488, Life Technologies). The cells were washed with PBS and mounted with Prolong Gold antifade reagent with DAPI (Life Technologies, USA). The slides were examined and analyzed using a laser-scanning confocal microscope system (Zeiss LSM 510 Meta laser-scanning confocal microscope).

Statistical analysis

Data analyses were performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). The results are shown as the mean ±SD. For data that were normally distributed, comparisons between groups were performed using a paired or unpaired t-test and ANOVA, as appropriate. Statistically significant differences between two clinical groups were analyzed using the nonparametric Mann–Whitney U-test.

Results

T2DM inhibits IL-22 production during Mtb infection

We used a previously published experimentally induced T2DM model for the current investigation (described in the methods section) [19]. One month after the induction of T2DM, control and T2DM mice were challenged with Mtb as shown in the schematic diagram (Fig 1A) and described in the methods section. One, three and five months post-Mtb infection, IL-22 levels in plasma and lung homogenate were significantly lower in Mtb-infected T2DM mice than in Mtb-infected nondiabetic control mice (Fig 1B and 1C). We also compared plasma IL-22 levels of TB patients with or without T2DM. As shown in Fig 1D, plasma IL-22 levels were significantly lower in patients with active TB and T2DM than in patients with TB without T2DM (20.80 ± 13.55 vs. 12.50 ± 11.24, p<0.05, Fig 1D).

Fig 1 — (A) T2DM induced in C57BL/6 mice with the intraperitoneal injection of streptozotocin (180 mg/kg body weight) and nicotinamide (60 mg/kg body weight) as described in the methods section. Control C57BL/6 or T2DM mice were infected with ~100 CFU of aerosolized *Mtb*. A schematic representation of T2DM induction and *Mtb* infection is shown. One, three, and five months after *Mtb* infection, the level of IL-22 was measured in the (B) plasma and (C) lung homogenate by ELISA. (D) Blood plasma samples were obtained from 32 patients with active pulmonary tuberculosis (TB) and 14 patients with TB and type 2 diabetes mellitus (T2DM). The level of IL-22 was determined by ELISA. Five mice per group were used. The mean values, SDs and p-values are shown.

Type 3 innate lymphoid cells produce IL-22 during Mtb infection

To determine the cellular source of IL-22, control and T2DM mice were challenged with aerosolized Mtb H37Rv as described in the methods section. We found that Mtb infection significantly increased the accumulation of lineage- and lineage+ IL-22 producing cells in the lung of control (lineage- cells: 0.18 ± 0.02 vs. 2.61 ± 0.08, p<0.01; lineage+ cells 0.36 ± 0.06 vs. 1.09 ± 0.05, p<0.01, Fig 2A) and T2DM mice (lineage- cells: 0.16 ± 0.02 vs. 0.85 ± 0.32, p<0.01; lineage+ cells: 0.09 ± 0.01 vs. 0.46 ± 0.03, p<0.01, Fig 2A). One month after Mtb infection, the lungs of control mice had 3.0-fold higher percentage of lineage-IL-22+ (2.61 ± 0.08 vs. 0.85 ± 0.32, p<0.01) and 2-fold higher lineage+IL-22+ (1.09 ± 0.05 vs. 0.46 ± 0.03, p<0.01) cells compared with the lungs of T2DM mice (Fig 2A and 2B). We further characterized the lineage+ and lineage- IL-22 producing cells in the major lymphoid organs of the control and T2DM mice after one, three and five months of Mtb infection. As shown in S1 Fig, among lineage+ lung cells, CD4+, CD8+, NK cells and γδ+ T cells produced IL-22, but the differences were not significant between Mtb-infected control and T2DM mice at one, three and five months post Mtb infection. Among lineage- cells, we were unable to detect any IL-22-producing type 1 innate lymphoid cells (ILC1) or type 2 innate lymphoid cells (ILC2) in various lymphoid organs of Mtb-infected control and T2DM mice at all three time points (one, three and five months after Mtb infection) (S2, S3A and S3B Figs) However, a significant number of lung and splenic ILC1s from Mtb-infected T2DM mice were positive for IFN-γ compared with those from the control Mtb-infected mice (S2, S3A and S4 Figs). In addition the number of ILC2s were reduced in the lung of Mtb-infected T2DM mice compared with control Mtb-infected mice at one, three and five months after infection (p<0.05, S3 and S5 Figs). Among the lineage -ve cell population, two subpopulations of ILC3s, both lymphoid tissue inducer (LTi) CD45+CD127+lin-Rorγ+NKp46-CCR6+ cells (50%) and NCR+ (CD45+CD127+lin- Rorγ+NKp46+CCR6-) cells (18%), were positive for IL-22, but the absolute number of the IL-22-producing LTi cells was significantly higher (8-10-fold in lung and 4-fold in spleen, Figs 2C, 2D, S6 and S7) in Mtb-infected control mice. IL-22-producing subsets of ILC3s, LTi and NCR+ also accumulate in the lungs of T2DM mice after Mtb infection compared to uninfected T2DM mice (p<0.05, Fig 2C–2F). However, as shown in Fig 2C–2F, both subpopulations of IL-22-producing ILC3s were significantly reduced in the lungs and spleens of Mtb-infected T2DM mice compared with those of the Mtb-infected control mice at one, three and five months after infection (lung LTi+IL-22+ cells: 1 month, p<0.05; 3 months, p<0.001; and 5 months, p<0.001; Fig 2C. Spleen LTi+IL-22+ cells: 1 month, not significant; 3 months, p<0.001; and 5 months, p<0.001; Fig 2D. Lung NCR+ cells: 1 month, not significant; 3 months, p<0.01; and 5 months, p<0.01; Fig 2E. Spleen NCR+ cells 1 month, p<0.05; 3 months, p<0.05; and 5 month, not significant; Fig 2F).

Fig 2 — Control C57BL/6 and T2DM mice were infected with *Mtb* as shown in Fig 1. (A) One month after *Mtb* infection, the percentage of lineage+IL-22+ and lineage-IL-22+ cells was determined by flow cytometry. (B) A representative flow cytometry plot is shown. (C-F) One, three and five months after *Mtb* infection, the absolute number of (C) lung LTi+IL-22+ cells, (D) splenic LTi+IL-22+ cells, (E) lung NCR+IL-22+ cells, and (F) splenic NCR+IL-22+ cells were determined by flow cytometry. Five mice per group were used. The mean values, SDs and p-values are shown.

Recombinant-IL-22 treatment prolongs the survival of Mtb-infected T2DM mice

Based on the above findings, we determined whether treatment with recombinant IL-22 affects survival, bacterial burden and certain insulin-dependent metabolic changes in Mtb-infected T2DM mice. Figs 3A and S8 show a schematic representation of Mtb infection and recombinant IL-22 treatment in T2DM mice. One month after T2DM induction, the mice were aerosol infected with ~100 CFU of Mtb, and at five months p.i., the mice were intravenously treated with a single dose or a twice weekly regimen (up to 35 weeks), of recombinant IL-22 (100 ng/kg body weight) or PBS as described in the methods section. As shown in Figs 3B and S8, 80% of Mtb-infected T2DM mice that received PBS died within 6.5 months of Mtb infection (median survival, 206.5 days p.i.). In contrast Mtb-infected T2DM mice that received a single dose of recombinant IL-22 survived up to 8.2 months (median survival, 206.5 vs. 247.5 days, p<0.05). Mice that received recombinant IL-22 (100 ng/kg body weight) twice a week survived up to 11.2 months after Mtb infection (median survival, 210.0 vs. 336.5 days p.i., p<0.001). Twice a weekly recombinant IL-22 treatment also reduced the bacterial burden in the lungs (Fig 3C). One month after twice a week recombinant IL-22 treatment in Mtb-infected T2DM mice, compared with PBS-treated Mtb-infected T2DM mice, serum insulin levels were significantly decreased (2.57 ± 0.17 vs. 1.55 ± 0.78, p<0.05, Fig 3D), and serum free fatty acids (460.9 ± 93.96 vs. 351.1 ± 34.87, p<0.05, Fig 3E) and triglycerides (174.7 ± 51.04 vs. 107.6 ± 4.98, p<0.05, Fig 3F) were marginally reduced. However, there was no significant change in blood glucose levels in single or multiple doses of recombinant IL-22 received mice (Figs 3H and S8C).

Fig 3 — One month after the induction of diabetes, T2DM mice were infected with ~100 CFU of aerosolized *Mtb*. Five months after *Mtb* infection, the mice were treated intravenously with recombinant IL-22 (100 ng/kg body weight, twice weekly) or PBS. (A) A schematic representation of *Mtb* infection and recombinant IL-22 treatment in T2DM mice is shown. (B) Survival of *Mtb*-infected T2DM mice treated with recombinant IL-22 or PBS. Survival curves were compared using the log rank test. Data were pooled from two independent experiments (n = 5 mice per group per experiment). (C) Bacterial burden in lungs at 1 month post recombinant IL-22 or PBS treatment. (D) Serum insulin levels were measured by ELISA at 1 month after recombinant IL-22 treatment. (E to G) free fatty acid, triglyceride and Serum cholesterol, levels were measured by biochemical-based assays at 1 month after recombinant IL-22 treatment. (H) Random blood glucose sampling at twenty-day intervals for up to 8 months. Five mice per group were used. The mean values, SDs and p-values are shown.

Because IL-22R is highly expressed by epithelial cells [33], in the above groups of mice, lung epithelial cells were isolated, and the expression of genes involved in the IL-22 signaling pathway was determined by PCR. As shown in Fig 4A, the expression of Bcl2 and stat5b was increased, and the expression of mapk9, il-10rb, fos, il-12rb2, mcl1, and Stat 4 was decreased in the epithelial cells from the lungs of recombinant IL-22-treated mice (100 ng/kg body weight, twice weekly) (Fig 4A). Recombinant IL-22 treatment also significantly enhanced the expression of genes involved in the production of antimicrobial peptides (Fig 4B).

Fig 4 — One month after the induction of diabetes, T2DM mice were infected with 50–100 CFU of aerosolized *Mtb*. The mice were then treated intravenously with either recombinant IL-22 (100 ng/kg body weight, twice weekly, starting 5 months p.i.) or PBS. One month after recombinant IL-22 or PBS treatment, lung epithelial cells were isolated by immunomagnetic labeling, and mRNA expression of (A) IL-22 signaling pathway genes and (B) antimicrobial genes were determined by real-time PCR. Five mice per group were used. The mean values, SDs and p-values are shown.

IL-22-producing ILC3s enhance the survival of Mtb-infected T2DM mice

As shown in Fig 2, lung ILC3s from Mtb-infected T2DM mice produced significantly less IL-22 than those from Mtb-infected nondiabetic mice. In the above experiment, we found that recombinant IL-22 treatment enhanced the survival of Mtb-infected T2DM mice. In another set of experiments we questioned whether the adoptive transfer of ILC3 subpopulations from control C57BL/6 mice to Mtb-infected T2DM mice could prolong their survival. We isolated NCR+ (Lin-CD127+NK1.1-NKp46+CCR6-) and LTi+ cells (Lin-CD127+NK1.1-NKp46-CCR6+) from pooled cells (from spleen, lung, liver, lymph nodes and mucosal sites) of CD45.1 mice (C57BL/6) as mentioned in the methods and shown in Fig 5A. Isolated LTi or NCR+ cells (0.5 x10⁵) were adoptively transferred through tail vein injections into C57BL/6 CD45.2 Mtb-infected T2DM mice on the 150^th day after Mtb infection. As shown in S9 A, adoptively transferred cells were detected in the lung at 15 and 30 days after adoptive transfer. Mtb-infected T2DM mice survived up to 205 days, and adoptive transfer of LTi+ cells enhanced their survival up to 253 days (Fig 5B, p<0.01). The adoptive transfer of NCR+ cells also enhanced the survival of Mtb-infected T2DM mice (median survival, 205 vs. 227 days, p<0.01, Fig 5B). One month after the adoptive transfer of ILC3 subpopulations, there were no significant changes in blood glucose or body weight of Mtb-infected T2DM mice (Fig 5C and 5D). In contrast, the level of serum triglycerides was significantly reduced (Fig 5E), and the level of IL-22 increased in the lung and plasma of Mtb-infected T2DM mice that received LTi+ cells compared with Mtb-infected T2DM mice that received PBS (S10A and S10B Fig).

Fig 5 — T2DM (CD45.2, C57BL/6 background) mice were infected with 50–100 CFU of aerosolized *Mtb*. Five months after *Mtb* infection, 0.5 x 10⁵ NCR+ (Lin-CD127+NK1.1-NKp46+CCR6-) or LTi+ (Lin-CD127+NK1.1-NKp46-CCR6+) pooled cells (from spleen, lung, liver, lymph nodes and mucosal sites) from CD45.1 mice (C57BL/6) were adoptively transferred via tail vein injection (recipient CD45.2 *Mtb*-infected T2DM mice). (A) A schematic representation of T2DM induction, *Mtb* infection and adoptive transfer is shown. (B) Survival of *Mtb*-infected T2DM mice treated with NCR+ or LTi or PBS. Data were pooled from two independent experiments (n = 5 mice per group per experiment). Survival curves were compared using the log rank test (p< 0.001). (C) Blood glucose and (D) weight were measured every 20 days up to 230 days post-*Mtb* infection. (E) Serum free fatty acid, triglyceride and cholesterol, levels at 1 month after adoptive transfer of the ILC3s. Data were pooled from two independent experiments (n = 3 mice per group per experiment). The mean values, SDs and p-values are shown.

IL-22 reduces the severity of lung inflammation and neutrophil-mediated damage of lung epithelial cells in Mtb-infected T2DM mice

We previously found that Mtb-infected T2DM mice had significantly more inflammation than Mtb-infected control mice or uninfected T2DM mice [19]. We determined the effect of recombinant IL-22 treatment on the lung pathology of Mtb-infected T2DM mice. In the above groups of mice, histological examination of the lungs demonstrated that compared with PBS treatment, recombinant IL-22 treatment significantly reduced lung inflammation (3.40 ± 0.6 vs. 1.80 ± 1.10, Fig 6A and 6B). IL-22R1 is mainly expressed by nonhematopoietic cells such as epithelial cells [33,40]. As shown in Fig 6C, in Mtb-infected T2DM mice (6 months after infection), the lung epithelial cell lining was severely damaged (disappearance of EpCAM+ cells), and IL-22R1 expression was reduced compared with that of Mtb-infected non-T2DM mice. Recombinant IL-22 treatment for 30 days significantly reduced epithelial cell damage and restored IL-22R1 expression (Fig 6C).

Fig 6 — One month after the induction of diabetes, T2DM mice were infected with ~100 CFU of aerosolized *Mtb* as shown in Fig 1 and described in the methods section. Five months after *Mtb* infection, T2DM mice were treated intravenously with either recombinant IL-22 (100 ng/kg body weight, twice weekly) or PBS. (A) After one month of recombinant IL-22 treatment, the lungs were isolated and formalin fixed. Paraffin-embedded tissue sections were prepared, and hematoxylin and eosin staining was performed. Lung inflammation scores were quantified by morphometric analysis. (B) Representative hematoxylin and eosin-stained lung tissue sections in multiple fields (at 40X and 100X) are shown. (C) Paraffin-embedded tissue sections were analyzed by confocal microscopy to determine the colocalization of EpCAM-positive cells (green) and IL-22R1+ cells (red). (D) Paraffin-embedded tissue sections were analyzed by confocal microscopy to determine the accumulation of the Ly6G+ cells (magenta) near the EpCAM+ epithelial cell lining (green). (E) The frequencies of Ly6G+ lung cell populations were determined by flow cytometry staining at 1 month after recombinant IL-22 treatment. (F-G) One month after PBS or recombinant IL-22 treatment, lung homogenates of the *Mtb-*infected T2DM mice were collected, and the levels of (F) myeloperoxidase (MPO) and (G) elastase were measured by ELISA. (H and I) T2DM (CD45.2, C57BL/6 background) mice were infected with 50–100 CFU of aerosolized *Mtb*. Five months after *Mtb* infection, 0.5 x 10⁵ NCR+ or LTi+ pooled cells (from spleen, lung, liver, lymph nodes and mucosal sites) from CD45.1 mice (C57BL/6) were adoptively transferred via tail vein injection (recipient CD45.2 *Mtb*-infected T2DM mice). (H) Elastase levels in the lung homogenate were measured by ELISA. (I) Ly6G+ cell accumulation near EpCAM+ cells (epithelial cell lining) in the lungs of ILC3- or PBS-treated *Mtb*-infected T2DM mice was analyzed by confocal microscopy. A representative immunofluorescence image is shown. Five mice per group were used. The mean values, SDs and p-values are shown.

Chronic inflammatory responses and ongoing proinflammatory signaling result in the influx of activated phagocytic cells towards the epithelial lining and induce its damage [41–43]. In the above groups of mice, we determined the infiltration of the phagocytic cells by confocal microscopy. As shown in Fig 6D, an increased number of Ly6G+ cells were observed in close proximity to the lung epithelial cell lining of the PBS-treated Mtb-infected T2DM mice. IL-22-treated Mtb-infected T2DM mice had a reduced accumulation of Ly6G+ cells near the lung epithelial cell lining. However, there was no difference in the recruitment of Ly6G+ cells (the total percentage of lung Ly6G+ cells was similar) in PBS- or rIL-22-treated Mtb-infected T2DM mice (Fig 6E). We did not find an accumulation of F4/80+ and CD11c+ phagocytic cells near the lung epithelial cell lining of Mtb-infected T2DM mice (S11A Fig). Ly6G+ cells contain cytotoxic substances, neutral proteinases and acid hydrolases, and direct interaction with epithelial cells induces the secretion of acid hydrolases and other enzymes that cause epithelial cell lining damage [44,45]. Five months after Mtb infection, we found increased infiltration of the Ly6G+ cells in the lung of T2DM mice compared with those of control mice (p<0.5, S12C Fig). As shown in S11B Fig, in the lungs of Mtb-infected T2DM mice (6 months after infection), the epithelial cell lining in the proximity of the Ly6G+ cells was disintegrated (losing membrane integrity) compared with that in the lungs of control mice infected with Mtb. We found a significant increase in neutrophil elastase 2 levels in the lung homogenate of Mtb-infected T2DM mice compared to that of Mtb-infected control mice (S12B Fig). Compared with the PBS control treatment, recombinant IL-22 treatment (1 month, twice weekly) reduced the infiltration of Ly6G+ cells in the epithelial cell lining and significantly reduced neutrophil elastase 2 levels in the lung homogenates of Mtb-infected T2DM mice (4.22 ±1.45 ng/ml vs. 2.18 ± 0.59 ng/ml, p<0.05; Fig 6G).

We further determined the elastase levels and epithelial cell damage in the lungs of Mtb-infected T2DM mice that received PBS or ILC3s. The level of neutrophil elastase 2 was significantly reduced in the lung homogenates of LTi-treated Mtb-infected T2DM mice compared with the lung homogenates of Mtb-infected T2DM mice (4.27 ± 1.46 vs. 1.86 ± 0.8, p<0.001, Fig 6H). Adoptive transfer of NCR+ cells also marginally reduced neutrophil elastase 2 level (4.27 ± 1.46 vs. 3.08 ± 0.54, p<0.05, Fig 6H). The adoptive transfer of LTi cells significantly reduced lung epithelial cell lining damage in T2DM mice infected with Mtb (Fig 6I).

IL-22 treatment maintains gut epithelial cell integrity in Mtb-infected T2DM mice

It is known that uncontrolled T2DM can damage the gut epithelial cell lining [46–48]. We determined whether recombinant IL-22 treatment can also prevent gut epithelial cell lining destruction and leakage. Control and T2DM mice were infected with aerosol Mtb H37Rv as shown in Fig 1A. At five months p.i., control, T2DM-infected and uninfected mice were orally gavaged with FITC dextran, and then, after 6 hours, FITC levels were measured in the blood. As shown in S13A Fig, FITC levels were significantly increased in T2DM mice compared with that of control mice (30.00 ± 12.00 vs. 178.0 ± 28.00, p<0.001). However, Mtb infection did not affect the serum FITC levels in the blood of control and T2DM mice (control: 30.00 ± 12.00 vs. control + Mtb: 50.00 ± 14.00, p = ns; T2DM: 178.0 ± 48.00 Vs. T2DM + Mtb: 210.0 ± 35.00, p = ns; S13A Fig). Twice weekly treatment with recombinant IL-22 reduced serum FITC levels in Mtb-infected T2DM mice (185.31 ± 28.8 vs. 141.4 ± 34.8, p<0.05; S13A and S13B Fig). Histological analysis also revealed that the gut epithelial lining of T2DM and Mtb-infected T2DM mice was disintegrated compared with that of control and Mtb-infected mice, and further treatment of Mtb-infected T2DM mice with recombinant IL-22 (twice weekly) for 1 month prevented the gut epithelial cell lining damage (S13C Fig).

Discussion

IL-22 plays an important role in the host defense against bacteria at mucosal surfaces, maintaining tissue barrier integrity by protecting epithelial cells and reducing chronic inflammation [40,49,50]. T2DM in Mtb-infected mice leads to a pathological immune response in the lung and enhances mortality [19]. In the current study, we investigated the role of IL-22 during Mtb infection in T2DM mice. We found that plasma IL-22 levels were significantly lower in Mtb-infected T2DM mice than in Mtb-infected nondiabetic mice. Similarly, IL-22 levels were significantly lower in TB patients with T2DM than in TB patients without T2DM. ILC3s were an important source of IL-22 in the lungs of Mtb-infected mice. Mtb-infected T2DM mouse lungs had fewer IL-22+ILC3+ cells than the lungs of Mtb-infected non-T2DM mice. Recombinant IL-22 and IL-22-producing ILC3+ subpopulations reduced the bacterial burden, lung epithelial cell damage, insulin level and lipid metabolites and prolonged the survival of Mtb-infected T2DM mice. Recombinant IL-22 treatment reduced the secretion of neutrophil elastase 2 by epithelial cell-associated neutrophils, which is known to damage epithelial cell lining in the lungs of Mtb-infected T2DM mice. Our findings demonstrate that IL-22 produced by ILC3s is essential to inhibit excess inflammation and epithelial cell damage in T2DM mice infected with Mtb.

Individuals with T2DM have a threefold increased chance of developing TB, and fifteen percent of the TB burden in the world is associated with T2DM [10,51–53]. T2DM is known to worsen the clinical features of TB and induce severe lung damage [2,54]. We recently found that natural killer (NK) and CD11c+ cell interactions in Mtb-infected T2DM mice led to increased IL-6 production, which drove the pathological immune response and reduced survival of Mtb-infected T2DM mice [19]. In our published studies, we found that except for IL-22, all pro- and anti-inflammatory cytokine levels (Th1, Th2 and Th17) were significantly higher in the lungs of Mtb-infected T2DM mice than in the lungs of nondiabetic Mtb-infected mice [19]. Similar findings were noted in the plasma of T2DM TB patients compared with that of TB patients without T2DM [26,55]. Our current findings confirm these findings and further demonstrate that ILC3s are an important source of IL-22 in Mtb-infected mouse lungs, and defective IL-22 production by ILC3s in T2DM mice infected with Mtb leads to epithelial cell damage and enhanced mortality.

In Mtb-infected T2DM mice, recombinant IL-22 treatment or adoptive transfer of ILC3s significantly reduced bacterial burden, reduced inflammation, improved lipid metabolism and prolonged survival in mice. We found that LTi cells, a subpopulation of ILC3, are more efficient than NCR+ cells in reducing inflammation and prolonging the survival of T2DM mice infected with Mtb. In addition, recombinant IL-22 treatment significantly alleviated insulin resistance in T2DM mice. IL-22 is known to play an important role in maintaining glucose homeostasis and insulin resistance and restores the mucosal host defense by bacterial clearance in various bacterial infections [36,37]. Our current study demonstrates for the first time that IL-22 and ILC3s can prevent excess inflammation and clear Mtb infection in T2DM and TB comorbid conditions, suggesting that IL-22 is a novel target for treating TB patients with T2DM.

IL-22 prevents experimental lung fibrosis, airway inflammation and tissue damage [56–59]. Previously, we found that Mtb infection induces severe immunopathology in the lungs of T2DM mice [19]. Furthermore, in the current study, we found a disintegrated epithelial barrier and loss of IL-22R expression by lung epithelial cells in T2DM mice infected with Mtb. Recombinant IL-22 treatment and ILC3 transfer prevented epithelial cell destruction, restored IL-22R expression, and resolved alveolar wall inflammation, which resulted in reduced alveolar destruction and fewer lesions in the lungs of T2DM mice infected with Mtb. We also found that IL-22 acted on lung epithelial cells to induce the expression of the anti-apoptotic proteins Bcl2 and Mcl1 and enhance antimicrobial peptide production by lung epithelial cells in T2DM mice infected with Mtb (Fig 4).

IL-22 can prevent pathogenic epithelial cell-destructive inflammation by inhibiting the release of matrix metalloproteases and PMN-recruiting chemokines and by promoting aberrant epithelial cell proliferation and differentiation [60–62]. We found an inverse correlation of IL-22 production with the level of elastase level and number of Ly6G+ cells in the lungs of the Mtb-infected T2DM mice. We found infiltrating Ly6G+ cells near the lung epithelial cell lining in Mtb-infected T2DM mice. Recombinant IL-22 treatment and ILC3 transfer had no effect on the total number of lung Ly6G+ cells but significantly reduced the infiltration of Ly6G+ cells near epithelial cells. Our results demonstrate that IL-22 prevents the accumulation of lung Ly6G+ cells near lung epithelial cells. Neutrophilic proteases can cleave IL-22R1 on epithelial cells and impair IL-22-dependent antimicrobial protein production from epithelial cells [63]. We found that neutrophils from T2DM mice infected with Mtb produced more neutrophil elastase 2 (ELA2) than nondiabetic mice infected with Mtb. Recombinant IL-22 treatment and ILC3 transfer decreased the production of neutrophil ELA2 in the lungs of Mtb-infected T2DM mice. ILC3s can also reduce CCL3 production and leukocyte recruitment at the site of injured tissue and ultimately inhibit inflammation [64,65]. Regulatory ILCs can also inhibit the generation of IL-17A/IFN-γ [66]. In addition to these findings, our study demonstrates for the first time that IL-22 and LTi cells prevent epithelial cell damage to inhibit infection-induced inflammation in a T2DM host. IL-22 is canonically associated with antimicrobial immunity [67]. IL-22 receptor signaling through STAT-3 in intestinal epithelial cells, induces the production of antimicrobial peptides [68]. Lung epithelial cell from IL-22 treated and Mtb infected T2DM mice had higher expression of the β-defensins, S100 calcium-binding proteins, and regenerating gene family (Reg) family proteins (Fig 4B). Our findings suggest that IL-22 treatment can control Mtb growth by inducing the production of anti-microbial proteins by lung epithelial cells in Mtb infected T2DM mice.

IL-22 is critical for the maintenance of the intestinal barrier function by promoting antipathogenic responses and the regeneration of epithelial cells [50,69]. We found that T2DM enhanced gut leakage in T2DM mice infected with Mtb and that recombinant IL-22 treatment prevented this permeability and maintained the integrity of the intestinal barrier (Fig 6). Our studies demonstrate that IL-22 not only prevents lung inflammation but also prevents gut leakage and maintains the integrity of the intestinal barrier to prevent other infections, the entry of dietary antigens into the circulation, pancreatic beta cell damage and insulin resistance in T2DM mice infected with Mtb. This defect in the lung enhances the susceptibility to Mtb infection, and in the colon, it allows bacteria to penetrate and induce systemic inflammation [43,70]. In addition, rIL-22 treatment and ILC3s adoptive transfer maintained glucose homeostasis and reduced dyslipidemia in Mtb infected T2DM mice. Our study demonstrates that IL-22 and ILC3s play an important role in mucosal defense and controlling the metabolic disorder in T2DM mice infected with Mtb.

In summary, our study demonstrates that IL-22 and ILC3s can prevent excess inflammation, reduce bacterial burden, improve lipid metabolism and prolong the survival of T2DM mice infected with Mtb. Further understanding of these mechanisms and human studies can help to treat TB patients with T2DM.

Supporting information

S1 Fig. IL-22 producing CD4, CD8, NK and γδ T cells in control and T2DM mice during Mtb infection.

Control C57BL/6 and T2DM mice were infected with Mtb as shown in Fig 1 and described in the methods section. One, three and five months after Mtb infection, the absolute numbers of (A) CD4+, (B) CD8, (C) NK cells and (D) γδ T cells per lung were determined by flow cytometry. Five mice per group were used. The mean values, SDs and p-values are shown.

(TIF)

Click here for additional data file.^{(708.6KB, tif)}

S2 Fig. Gating strategy for the identification of ILC1s in mouse lung.

Control C57BL/6 mice were infected with Mtb as shown in Fig 1 and described in the methods section. One, three and five post Mtb infection lung single cell suspension was prepared and flow cytometry was performed. Flow gating strategy for ILC1s (CD45+CD127+lin-NKp46+NK1.1+) are shown.

(TIF)

Click here for additional data file.^{(539.5KB, tif)}

S3 Fig. Gating strategy for the identification of IL-22 producing ILC1s and ILCs 2 in mouse lung.

Control C57BL/6 mice were infected with Mtb as shown in Fig 1 and described in the methods section. One, three and five post Mtb infection lung single cell suspension was prepared and flow cytometry was performed. (A) Flow gating strategy for IL-22 and IFN-γ producing ILC1s (CD45+CD127+lin-NKp46+NK1.1+) and (B) IL-22 producing ILC2s (CD45+CD127+lin-Rorγt-Sca1+) are shown.

(TIF)

Click here for additional data file.^{(370.1KB, tif)}

S4 Fig. Interferon-gamma (IFN-γ)-producing type 1 innate lymphoid cells (ILC1s) in control and T2DM mice during Mtb infection.

Control C57BL/6 and T2DM mice were infected with Mtb as shown in Fig 1 and described in the methods section. (A-D) One, three and five months after Mtb infection, the absolute number of ILC1 (CD45+CD127+lin-NKp46+NK1.1+) IFN-γ+ cells per 10⁶ cells in (A), lung, (B) spleen, (C), inguinal lymph nodes and (D) liver was determined by flow cytometry. Five mice per group were used. The mean values, SDs and p-values are shown.

(TIF)

Click here for additional data file.^{(360.8KB, tif)}

S5 Fig. Type 2 innate lymphoid cells (ILC2s) in control and T2DM mice during Mtb infection.

Control C57BL/6 and T2DM mice were infected with Mtb as shown in Fig 1 and described in the methods section. (A-B) One, three and five months after Mtb infection, the absolute number of ILC2s (CD45+CD127+lin-Rorγt-Sca1+) per 10⁶ cells in (A) spleen and (B) lung was determined by flow cytometry. Five mice per group were used. The mean values, SDs and p-values are shown.

(TIF)

Click here for additional data file.^{(172.5KB, tif)}

S6 Fig. Gating strategy for the identification of ILC2s and ILC3s in mouse lung.

Control C57BL/6 and T2DM mice were infected with Mtb as shown in Fig 1 and described in the methods section. One, three and five post Mtb infection lung single cell suspension were prepared and flow cytometry was performed. Flow gating strategies for ILC2s (CD45+CD127+lin-Rorγt-Sca1+) and ILC3s subpopulation LTi (CD45+CD127+lin-NK1.1-Rorγt+NKp46-CCR6+) and NCR+ (CD45+CD127+lin-NK1.1-Rorγt+NKp46+CCR6-) are shown.

(TIF)

Click here for additional data file.^{(683.7KB, tif)}

S7 Fig. IL-22 producing subpopulation of ILC3s.

Control C57BL/6 and T2DM mice were infected with Mtb as shown in Fig 1 and described in the methods section. One, three and five months post Mtb infection lung single cell suspension was prepared and flowcytometry was performed. A representative flow cytometry figure for IL-22 producing (A) LTi and (B) NCR+ ILC3s is shown.

(TIF)

Click here for additional data file.^{(477.1KB, tif)}

S8 Fig. Recombinant-IL-22 treatment prolongs the survival of Mtb-infected T2DM mice.

One month after the induction of diabetes, T2DM mice were infected with ~100 CFU of aerosolized Mtb. Five months after Mtb infection, mice were treated intravenously with recombinant IL-22 (100 ng/kg body weight, single dose) or PBS. (A) Schematic representation of Mtb infection and recombinant IL-22 treatment in T2DM mice is shown. (B) Survival of Mtb-infected T2DM mice treated with recombinant IL-22 or PBS. Survival curves were compared using the log rank test. Data were pooled from two independent experiments (n = 5 mice per group per experiment used). (C) Random blood glucose sampling at twenty-day intervals for up to 8 months. Five mice per group were used. The mean values, SDs and p-values are shown.

(TIF)

Click here for additional data file.^{(222.5KB, tif)}

S9 Fig. Adoptive transfer of type 3 innate lymphoid cells (ILC3s) enhances the survival of Mtb-infected T2DM mice.

T2DM (CD45.2, C57BL/6 background) mice were infected with ~100 CFU of aerosolized Mtb. Five months after Mtb infection, 0.5 x 10⁵ NCR+ (Lin-CD127+NK1.1-NKp46+CCR6-) or LTi+ (Lin-CD127+NK1.1-NKp46-CCR6+) pooled cells (from spleen, lung, liver, lymph nodes and mucosal sites) from CD45.1 mice (C57BL/6) were adoptively transferred via tail vein injection (recipient CD45.2 Mtb-infected T2DM mice). Fifteen and thirty days after adoptive transfer, CD45.1+ILC3+ cells were analyzed in the (A) lung, (B) spleen and (C) liver by flow cytometry.

(TIF)

Click here for additional data file.^{(1.6MB, tif)}

S10 Fig. IL-22 levels in the lungs after adoptive transfer of ILC3s.

T2DM (CD45.2, C57BL/6 background) mice were infected with ~100 CFU of aerosolized Mtb. Five months after Mtb infection, NCR+ (Lin-CD127+NK1.1-NKp46+CCR6-) or LTi+ (Lin-CD127+NK1.1-NKp46-CCR6+) cells were isolated from pooled spleen, lung, liver, lymph nodes of CD45.1 mice (C57BL/6). 0.5 x 10⁵ NCR+ (Lin-CD127+NK1.1-NKp46+CCR6-) or LTi+ (Lin-CD127+NK1.1-NKp46-CCR6+) cells were adoptively transferred to CD45.2 Mtb-infected T2DM mice (recipient) via tail vein injection. Thirty days after adoptive transfer, the level of IL-22 was measured in the (A) lung homogenate and (B) plasma of recipient mice by ELISA. Five mice per group were used. The mean values, SDs and p-values are shown.

(TIF)

Click here for additional data file.^{(261.3KB, tif)}

S11 Fig. Accumulation of phagocytic cells near the alveolar epithelial cell lining in recombinant IL-22-treated Mtb-infected T2DM mice.

One month after the induction of diabetes, T2DM mice were infected with ~100 CFU of aerosolized Mtb as shown in Fig 1 and described in the methods section. Five months after Mtb infection, T2DM mice were treated intravenously with either recombinant IL-22 (100 ng/kg body weight, twice weekly) or PBS. (A) After one month of recombinant IL-22 treatment, the lungs were isolated and formalin fixed. Paraffin-embedded tissue sections were prepared, and immunofluorescence staining was performed. Stained tissue sections were analyzed by confocal microscopy to determine the accumulation of F4/80+ (magenta) and CD11C+ (red) cells near EpCAM+ cells (green). (B) Paraffin-embedded tissue sections were analyzed by confocal microscopy to determine the accumulation of Ly6G+ cells (magenta) near the alveolar epithelial cell lining (green).

(TIF)

Click here for additional data file.^{(1.1MB, tif)}

S12 Fig. Level of myeloperoxidase (MPO) and elastase 2 in the lung homogenate of control and T2DM mice during Mtb infection.

Control C57BL/6 and T2DM mice were infected with Mtb as shown in Fig 1 and described in the methods section. Five months after Mtb infection, (A) MPO and (B) elastase levels were measured in lung homogenates by ELISA. (C) The frequency of the Ly6G+ cells was measured by flow cytometry. Five mice per group were used. The mean values, SDs and p-values are shown.

(TIF)

Click here for additional data file.^{(295.4KB, tif)}

S13 Fig. IL-22 treatment maintains gut epithelial cell integrity in Mtb-infected T2DM mice.

Control and T2DM mice were infected with 50–100 CFU of aerosolized Mtb. Five months after Mtb infection, gut permeability was determined by the oral delivery of fluorescein isothiocyanate-dextran (FITC-dextran) (44 mg/100 gm body weight). (A) Six hours after oral delivery, the serum level of FITC-dextran was measured by fluorometry. (B) Five months after Mtb infection, T2DM mice were treated intravenously with either recombinant IL-22 (100 ng/kg body weight, twice weekly) or PBS. One month after recombinant IL-22 or PBS treatment, FITC-dextran was orally delivered, and after six hours, serum FITC-dextran level were measured. Five mice per group were used. The mean values, SDs and p-values are shown. (C) After one month of recombinant IL-22 treatment, the small intestine was isolated and formalin fixed. Paraffin-embedded intestinal tissue sections were prepared, and hematoxylin and eosin staining was performed. Representative hematoxylin- and eosin-stained small intestine tissue sections are shown. Five mice per group were used.

(TIF)

Click here for additional data file.^{(874.9KB, tif)}

S1 Table. Demographic details.

(DOCX)

Click here for additional data file.^{(21.2KB, docx)}

S2 Table. List of primers used in this study.

(DOCX)

Click here for additional data file.^{(15.9KB, docx)}

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was supported by grants from the National Institutes of Health (R01AI123310 and R21A1085135 to R. V.), CRDF-global- (USB1-31148-XX-13), the Cain Foundation for Infectious Disease Research and the Department of Pulmonary Immunology, University of Texas Health Science Center at Tyler, Texas, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1.Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Fay MP, Nutman TB, et al. Type 2 diabetes mellitus coincident with pulmonary tuberculosis is associated with heightened systemic type 1, type 17, and other proinflammatory cytokines. Ann Am Thorac Soc. 2013;10: 441–449. 10.1513/AnnalsATS.201305-112OC [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Ronacher K, Joosten SA, van Crevel R, Dockrell HM, Walzl G, Ottenhoff THM. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunol Rev. 2015;264: 121–137. 10.1111/imr.12257 [DOI] [PubMed] [Google Scholar]
3.Lachmandas E, van den Heuvel CNAM, Damen MSMA, Cleophas MCP, Netea MG, van Crevel R. Diabetes Mellitus and Increased Tuberculosis Susceptibility: The Role of Short-Chain Fatty Acids. J Diabetes Res. 2016;2016 10.1155/2016/6014631 [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Kumar Nathella P, Babu S. Influence of diabetes mellitus on immunity to human tuberculosis. Immunology. 2017;152: 13–24. 10.1111/imm.12762 [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Cernea S, Dobreanu M. Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem Med (Zagreb). 2013;23: 266–280. 10.11613/BM.2013.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Chng MHY, Alonso MN, Barnes SE, Nguyen KD, Engleman EG. Adaptive Immunity and Antigen-Specific Activation in Obesity-Associated Insulin Resistance. Mediators Inflamm. 2015;2015 10.1155/2015/593075 [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol. 2014;44: 617–626. 10.1002/eji.201344301 [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Lee M-R, Huang Y-P, Kuo Y-T, Luo C-H, Shih Y-J, Shu C-C, et al. Diabetes Mellitus and Latent Tuberculosis Infection: A Systemic Review and Metaanalysis. Clin Infect Dis. 2017;64: 719–727. 10.1093/cid/ciw836 [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis. Am J Trop Med Hyg. 2009;80: 634–639. [PMC free article] [PubMed] [Google Scholar]
10.Restrepo BI. Diabetes and tuberculosis. Microbiol Spectr. 2016;4 10.1128/microbiolspec.TNMI7-0023-2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Zheng H, Wu J, Jin Z, Yan L-J. Potential Biochemical Mechanisms of Lung Injury in Diabetes. Aging Dis. 2017;8: 7–16. 10.14336/AD.2016.0627 [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Mayer-Barber KD, Barber DL. Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection. Cold Spring Harb Perspect Med. 2015;5 10.1101/cshperspect.a018424 [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Vallerskog T, Martens GW, Kornfeld H. Diabetic Mice Display a Delayed Adaptive Immune Response to Mycobacterium tuberculosis. J Immunol. 2010;184: 6275–6282. 10.4049/jimmunol.1000304 [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Domingo-Gonzalez R, Prince O, Cooper A, Khader S. Cytokines and Chemokines in Mycobacterium tuberculosis infection. Microbiol Spectr. 2016;4 10.1128/microbiolspec.TBTB2-0018-2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Sampath P, Moideen K, Ranganathan UD, Bethunaickan R. Monocyte Subsets: Phenotypes and Function in Tuberculosis Infection. Front Immunol. 2018;9 10.3389/fimmu.2018.00009 [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Stew SS, Martinez PJ, Schlesinger LS, Restrepo BI. Differential expression of monocyte surface markers among TB patients with diabetes co-morbidity. Tuberculosis (Edinb). 2013;93: S78–S82. 10.1016/S1472-9792(13)70015-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Wang CH, Yu CT, Lin HC, Liu CY, Kuo HP. Hypodense alveolar macrophages in patients with diabetes mellitus and active pulmonary tuberculosis. Tuber Lung Dis. 1999;79: 235–242. 10.1054/tuld.1998.0167 [DOI] [PubMed] [Google Scholar]
18.Kumar NP, Moideen K, Viswanathan V, Sivakumar S, Menon PA, Kornfeld H, et al. Heightened circulating levels of antimicrobial peptides in tuberculosis—Diabetes co-morbidity and reversal upon treatment. PLoS One. 2017;12 10.1371/journal.pone.0184753 [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Cheekatla SS, Tripathi D, Venkatasubramanian S, Nathella PK, Paidipally P, Ishibashi M, et al. NK-CD11c+ Cell Crosstalk in Diabetes Enhances IL-6-Mediated Inflammation during Mycobacterium tuberculosis Infection. PLoS Pathog. 2016;12: e1005972 10.1371/journal.ppat.1005972 [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Eberl G, Colonna M, Di Santo JP, McKenzie ANJ. Innate Lymphoid Cells: a new paradigm in immunology. Science. 2015;348: aaa6566 10.1126/science.aaa6566 [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Vivier E, van de Pavert SA, Cooper MD, Belz GT. The evolution of innate lymphoid cells. Nat Immunol. 2016;17: 790–794. 10.1038/ni.3459 [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Ebbo M, Crinier A, Vély F, Vivier E. Innate lymphoid cells: major players in inflammatory diseases. Nature Reviews Immunology. 2017;17: 665–678. 10.1038/nri.2017.86 [DOI] [PubMed] [Google Scholar]
23.Bando JK, Colonna M. Innate lymphoid cell function in the context of adaptive immunity. Nat Immunol. 2016;17: 783–789. 10.1038/ni.3484 [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Ardain A, Domingo-Gonzalez R, Das S, Kazer SW, Howard NC, Singh A, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature. 2019;570: 528–532. 10.1038/s41586-019-1276-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LVM, et al. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol. 2009;183: 6639–6645. 10.4049/jimmunol.0902587 [DOI] [PubMed] [Google Scholar]
26.Ronacher K, Sinha R, Cestari M. IL-22: An Underestimated Player in Natural Resistance to Tuberculosis? Front Immunol. 2018;9 10.3389/fimmu.2018.00009 [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Treerat P, Prince O, Cruz-Lagunas A, Muñoz-Torrico M, Salazar-Lezama MA, Selman M, et al. Novel role for IL-22 in protection during chronic Mycobacterium tuberculosis HN878 infection. Mucosal Immunol. 2017;10: 1069–1081. 10.1038/mi.2017.15 [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Dhiman R, Periasamy S, Barnes PF, Jaiswal AG, Paidipally P, Barnes AB, et al. NK1. 1+ cells and IL-22 regulate vaccine-induced protective immunity against challenge with Mycobacterium tuberculosis. The Journal of Immunology. 2012;189: 897–905. 10.4049/jimmunol.1102833 [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Yi P, Liang Y, Yuan DMK, Jie Z, Kwota Z, Chen Y, et al. A tightly regulated IL-22 response maintains immune functions and homeostasis in systemic viral infection. Scientific Reports. 2017;7: 3857 10.1038/s41598-017-04260-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
30.Gimeno Brias S, Stack G, Stacey MA, Redwood AJ, Humphreys IR. The Role of IL-22 in Viral Infections: Paradigms and Paradoxes. Front Immunol. 2016;7 10.3389/fimmu.2016.00007 [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Alabbas SY, Begun J, Florin TH, Oancea I. The role of IL‐22 in the resolution of sterile and nonsterile inflammation. Clin Transl Immunology. 2018;7 10.1002/cti2.1017 [DOI] [PMC free article] [PubMed] [Google Scholar]
32.Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol. 2011;23: 159–163. 10.1093/intimm/dxr001 [DOI] [PubMed] [Google Scholar]
33.Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol. 2010;107: 1–29. 10.1016/B978-0-12-381300-8.00001-0 [DOI] [PubMed] [Google Scholar]
34.Kumar NP, Banurekha VV, Nair D, Kumaran P, Dolla CK, Babu S. Type 2 diabetes—tuberculosis co-morbidity is associated with diminished circulating levels of IL-20 subfamily of cytokines. Tuberculosis (Edinb). 2015;95: 707–712. 10.1016/j.tube.2015.06.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Ronacher K, van Crevel R, Critchley JA, Bremer AA, Schlesinger LS, Kapur A, et al. Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mechanisms. Chest. 2017;152: 174–180. 10.1016/j.chest.2017.02.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
36.Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014;514: 237–241. 10.1038/nature13564 [DOI] [PubMed] [Google Scholar]
37.Hasnain SZ, Borg DJ, Harcourt BE, Tong H, Sheng YH, Ng CP, et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med. 2014;20: 1417–1426. 10.1038/nm.3705 [DOI] [PubMed] [Google Scholar]
38.Woting A, Blaut M. Small Intestinal Permeability and Gut-Transit Time Determined with Low and High Molecular Weight Fluorescein Isothiocyanate-Dextrans in C3H Mice. Nutrients. 2018;10 10.3390/nu10060685 [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Venkatasubramanian S, Tripathi D, Tucker T, Paidipally P, Cheekatla S, Welch E, et al. Tissue factor expression by myeloid cells contributes to protective immune response against Mycobacterium tuberculosis infection. Eur J Immunol. 2015. 10.1002/eji.201545817 [DOI] [PMC free article] [PubMed] [Google Scholar]
40.Fukaya T, Fukui T, Uto T, Takagi H, Nasu J, Miyanaga N, et al. Pivotal Role of IL-22 Binding Protein in the Epithelial Autoregulation of Interleukin-22 Signaling in the Control of Skin Inflammation. Front Immunol. 2018;9 10.3389/fimmu.2018.00009 [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9: 7204–7218. 10.18632/oncotarget.23208 [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol. 2008;3: 99–126. 10.1146/annurev.pathmechdis.3.121806.151456 [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Robb CT, Regan KH, Dorward DA, Rossi AG. Key mechanisms governing resolution of lung inflammation. Semin Immunopathol. 2016;38: 425–448. 10.1007/s00281-016-0560-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
44.McDonough KA, Kress Y. Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infect Immun. 1995;63: 4802–4811. [DOI] [PMC free article] [PubMed] [Google Scholar]
45.Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil Function: From Mechanisms to Disease. Annual Review of Immunology. 2012;30: 459–489. 10.1146/annurev-immunol-020711-074942 [DOI] [PubMed] [Google Scholar]
46.König J, Wells J, Cani PD, García-Ródenas CL, MacDonald T, Mercenier A, et al. Human Intestinal Barrier Function in Health and Disease. Clin Transl Gastroenterol. 2016;7: e196 10.1038/ctg.2016.54 [DOI] [PMC free article] [PubMed] [Google Scholar]
47.de Kort S, Keszthelyi D, Masclee A a. M. Leaky gut and diabetes mellitus: what is the link? Obes Rev. 2011;12: 449–458. 10.1111/j.1467-789X.2010.00845.x [DOI] [PubMed] [Google Scholar]
48.Zhao M, Liao D, Zhao J. Diabetes-induced mechanophysiological changes in the small intestine and colon. World J Diabetes. 2017;8: 249–269. 10.4239/wjd.v8.i6.249 [DOI] [PMC free article] [PubMed] [Google Scholar]
49.Valeri M, Raffatellu M. Cytokines IL-17 and IL-22 in the host response to infection. Pathog Dis. 2016;74 10.1093/femspd/ftw111 [DOI] [PMC free article] [PubMed] [Google Scholar]
50.Lo BC, Shin SB, Hernaez DC, Refaeli I, Yu HB, Goebeler V, et al. IL-22 Preserves Gut Epithelial Integrity and Promotes Disease Remission during Chronic Salmonella Infection. The Journal of Immunology. 2019; ji1801308 10.4049/jimmunol.1801308 [DOI] [PubMed] [Google Scholar]
51.Zheng C, Hu M, Gao F. Diabetes and pulmonary tuberculosis: a global overview with special focus on the situation in Asian countries with high TB-DM burden. Glob Health Action. 2017;10 10.1080/16549716.2016.1264702 [DOI] [PMC free article] [PubMed] [Google Scholar]
52.Berkowitz N, Okorie A, Goliath R, Levitt N, Wilkinson RJ, Oni T. The prevalence and determinants of active tuberculosis among diabetes patients in Cape Town, South Africa, a high HIV/TB burden setting. Diabetes Res Clin Pract. 2018;138: 16–25. 10.1016/j.diabres.2018.01.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
53.Leegaard A, Riis A, Kornum JB, Prahl JB, Thomsen VØ, Sørensen HT, et al. Diabetes, Glycemic Control, and Risk of Tuberculosis: A population-based case-control study. Diabetes Care. 2011;34: 2530–2535. 10.2337/dc11-0902 [DOI] [PMC free article] [PubMed] [Google Scholar]
54.Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9: 737–746. 10.1016/S1473-3099(09)70282-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
55.Kumar NP, Nair D, Banurekha VV, Chandrakumar D, Kumaran P, Sridhar R, et al. Type 2 diabetes mellitus coincident with pulmonary or latent tuberculosis results in modulation of adipocytokines. Cytokine. 2016;79: 74–81. 10.1016/j.cyto.2015.12.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
56.Dudakov JA, Hanash AM, van den Brink MRM. Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015;33: 747–785. 10.1146/annurev-immunol-032414-112123 [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Bayes HK, Ritchie ND, Ward C, Corris PA, Brodlie M, Evans TJ. IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection. J Cyst Fibros. 2016;15: 759–768. 10.1016/j.jcf.2016.06.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
58.Felton JM, Duffin R, Robb CT, Crittenden S, Anderton SM, Howie SEM, et al. Facilitation of IL-22 production from innate lymphoid cells by prostaglandin E2 prevents experimental lung neutrophilic inflammation. Thorax. 2018;73: 1081–1084. 10.1136/thoraxjnl-2017-211097 [DOI] [PMC free article] [PubMed] [Google Scholar]
59.Ivanov S, Renneson J, Fontaine J, Barthelemy A, Paget C, Fernandez EM, et al. Interleukin-22 Reduces Lung Inflammation during Influenza A Virus Infection and Protects against Secondary Bacterial Infection. Journal of Virology. 2013;87: 6911–6924. 10.1128/JVI.02943-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
60.Andrews C, McLean MH, Durum SK. Cytokine Tuning of Intestinal Epithelial Function. Front Immunol. 2018;9 10.3389/fimmu.2018.00009 [DOI] [PMC free article] [PubMed] [Google Scholar]
61.Rendon JL, Li X, Akhtar S, Choudhry MA. IL-22 modulates gut epithelial and immune barrier functions following acute alcohol exposure and burn injury. Shock. 2013;39: 11–18. 10.1097/SHK.0b013e3182749f96 [DOI] [PMC free article] [PubMed] [Google Scholar]
62.Lanfranca MP, Lin Y, Fang J, Zou W, Frankel T. Biological and Pathological Activities of Interleukin-22. J Mol Med (Berl). 2016;94: 523–534. 10.1007/s00109-016-1391-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
63.Guillon A, Jouan Y, Brea D, Gueugnon F, Dalloneau E, Baranek T, et al. Neutrophil proteases alter the interleukin-22-receptor-dependent lung antimicrobial defence. European Respiratory Journal. 2015;46: 771–782. 10.1183/09031936.00215114 [DOI] [PubMed] [Google Scholar]
64.Li Z, Hodgkinson T, Gothard EJ, Boroumand S, Lamb R, Cummins I, et al. Epidermal Notch1 recruits RORγ⁺ group 3 innate lymphoid cells to orchestrate normal skin repair. Nature Communications. 2016;7: 11394 10.1038/ncomms11394 [DOI] [PMC free article] [PubMed] [Google Scholar]
65.Cella M, Miller H, Song C. Beyond NK Cells: The Expanding Universe of Innate Lymphoid Cells. Front Immunol. 2014;5 10.3389/fimmu.2014.00005 [DOI] [PMC free article] [PubMed] [Google Scholar]
66.Wang S, Xia P, Chen Y, Qu Y, Xiong Z, Ye B, et al. Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation. Cell. 2017;171: 201–216.e18. 10.1016/j.cell.2017.07.027 [DOI] [PubMed] [Google Scholar]
67.Ouyang W, O’Garra A. IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity. 2019;50: 871–891. 10.1016/j.immuni.2019.03.020 [DOI] [PubMed] [Google Scholar]
68.Mühl H, Scheiermann P, Bachmann M, Härdle L, Heinrichs A, Pfeilschifter J. IL-22 in tissue-protective therapy. Br J Pharmacol. 2013;169: 761–771. 10.1111/bph.12196 [DOI] [PMC free article] [PubMed] [Google Scholar]
69.Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease. Cellular and Molecular Gastroenterology and Hepatology. 2017;4: 33–46. 10.1016/j.jcmgh.2017.03.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
70.Armstrong LE, Lee EC, Armstrong EM. Interactions of Gut Microbiota, Endotoxemia, Immune Function, and Diet in Exertional Heatstroke. In: Journal of Sports Medicine [Internet]. 2018. [cited 28 Mar 2019]. 10.1155/2018/5724575 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Fig. IL-22 producing CD4, CD8, NK and γδ T cells in control and T2DM mice during Mtb infection.

(TIF)

Click here for additional data file.^{(708.6KB, tif)}

S2 Fig. Gating strategy for the identification of ILC1s in mouse lung.

(TIF)

Click here for additional data file.^{(539.5KB, tif)}

S3 Fig. Gating strategy for the identification of IL-22 producing ILC1s and ILCs 2 in mouse lung.

Control C57BL/6 mice were infected with Mtb as shown in Fig 1 and described in the methods section. One, three and five post Mtb infection lung single cell suspension was prepared and flow cytometry was performed. (A) Flow gating strategy for IL-22 and IFN-γ producing ILC1s (CD45+CD127+lin-NKp46+NK1.1+) and (B) IL-22 producing ILC2s (CD45+CD127+lin-Rorγt-Sca1+) are shown.

(TIF)

Click here for additional data file.^{(370.1KB, tif)}

S4 Fig. Interferon-gamma (IFN-γ)-producing type 1 innate lymphoid cells (ILC1s) in control and T2DM mice during Mtb infection.

(TIF)

Click here for additional data file.^{(360.8KB, tif)}

S5 Fig. Type 2 innate lymphoid cells (ILC2s) in control and T2DM mice during Mtb infection.

(TIF)

Click here for additional data file.^{(172.5KB, tif)}

S6 Fig. Gating strategy for the identification of ILC2s and ILC3s in mouse lung.

(TIF)

Click here for additional data file.^{(683.7KB, tif)}

S7 Fig. IL-22 producing subpopulation of ILC3s.

(TIF)

Click here for additional data file.^{(477.1KB, tif)}

S8 Fig. Recombinant-IL-22 treatment prolongs the survival of Mtb-infected T2DM mice.

(TIF)

Click here for additional data file.^{(222.5KB, tif)}

S9 Fig. Adoptive transfer of type 3 innate lymphoid cells (ILC3s) enhances the survival of Mtb-infected T2DM mice.

(TIF)

Click here for additional data file.^{(1.6MB, tif)}

S10 Fig. IL-22 levels in the lungs after adoptive transfer of ILC3s.

(TIF)

Click here for additional data file.^{(261.3KB, tif)}

S11 Fig. Accumulation of phagocytic cells near the alveolar epithelial cell lining in recombinant IL-22-treated Mtb-infected T2DM mice.

(TIF)

Click here for additional data file.^{(1.1MB, tif)}

S12 Fig. Level of myeloperoxidase (MPO) and elastase 2 in the lung homogenate of control and T2DM mice during Mtb infection.

(TIF)

Click here for additional data file.^{(295.4KB, tif)}

S13 Fig. IL-22 treatment maintains gut epithelial cell integrity in Mtb-infected T2DM mice.

(TIF)

Click here for additional data file.^{(874.9KB, tif)}

S1 Table. Demographic details.

(DOCX)

Click here for additional data file.^{(21.2KB, docx)}

S2 Table. List of primers used in this study.

(DOCX)

Click here for additional data file.^{(15.9KB, docx)}

Data Availability Statement

All relevant data are within the manuscript and its Supporting Information files.

[ppat.1008140.ref001] 1.Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Fay MP, Nutman TB, et al. Type 2 diabetes mellitus coincident with pulmonary tuberculosis is associated with heightened systemic type 1, type 17, and other proinflammatory cytokines. Ann Am Thorac Soc. 2013;10: 441–449. 10.1513/AnnalsATS.201305-112OC [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref002] 2.Ronacher K, Joosten SA, van Crevel R, Dockrell HM, Walzl G, Ottenhoff THM. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunol Rev. 2015;264: 121–137. 10.1111/imr.12257 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref003] 3.Lachmandas E, van den Heuvel CNAM, Damen MSMA, Cleophas MCP, Netea MG, van Crevel R. Diabetes Mellitus and Increased Tuberculosis Susceptibility: The Role of Short-Chain Fatty Acids. J Diabetes Res. 2016;2016 10.1155/2016/6014631 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref004] 4.Kumar Nathella P, Babu S. Influence of diabetes mellitus on immunity to human tuberculosis. Immunology. 2017;152: 13–24. 10.1111/imm.12762 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref005] 5.Cernea S, Dobreanu M. Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem Med (Zagreb). 2013;23: 266–280. 10.11613/BM.2013.033 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref006] 6.Chng MHY, Alonso MN, Barnes SE, Nguyen KD, Engleman EG. Adaptive Immunity and Antigen-Specific Activation in Obesity-Associated Insulin Resistance. Mediators Inflamm. 2015;2015 10.1155/2015/593075 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref007] 7.Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol. 2014;44: 617–626. 10.1002/eji.201344301 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref008] 8.Lee M-R, Huang Y-P, Kuo Y-T, Luo C-H, Shih Y-J, Shu C-C, et al. Diabetes Mellitus and Latent Tuberculosis Infection: A Systemic Review and Metaanalysis. Clin Infect Dis. 2017;64: 719–727. 10.1093/cid/ciw836 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref009] 9.Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis. Am J Trop Med Hyg. 2009;80: 634–639. [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref010] 10.Restrepo BI. Diabetes and tuberculosis. Microbiol Spectr. 2016;4 10.1128/microbiolspec.TNMI7-0023-2016 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref011] 11.Zheng H, Wu J, Jin Z, Yan L-J. Potential Biochemical Mechanisms of Lung Injury in Diabetes. Aging Dis. 2017;8: 7–16. 10.14336/AD.2016.0627 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref012] 12.Mayer-Barber KD, Barber DL. Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection. Cold Spring Harb Perspect Med. 2015;5 10.1101/cshperspect.a018424 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref013] 13.Vallerskog T, Martens GW, Kornfeld H. Diabetic Mice Display a Delayed Adaptive Immune Response to Mycobacterium tuberculosis. J Immunol. 2010;184: 6275–6282. 10.4049/jimmunol.1000304 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref014] 14.Domingo-Gonzalez R, Prince O, Cooper A, Khader S. Cytokines and Chemokines in Mycobacterium tuberculosis infection. Microbiol Spectr. 2016;4 10.1128/microbiolspec.TBTB2-0018-2016 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref015] 15.Sampath P, Moideen K, Ranganathan UD, Bethunaickan R. Monocyte Subsets: Phenotypes and Function in Tuberculosis Infection. Front Immunol. 2018;9 10.3389/fimmu.2018.00009 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref016] 16.Stew SS, Martinez PJ, Schlesinger LS, Restrepo BI. Differential expression of monocyte surface markers among TB patients with diabetes co-morbidity. Tuberculosis (Edinb). 2013;93: S78–S82. 10.1016/S1472-9792(13)70015-5 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref017] 17.Wang CH, Yu CT, Lin HC, Liu CY, Kuo HP. Hypodense alveolar macrophages in patients with diabetes mellitus and active pulmonary tuberculosis. Tuber Lung Dis. 1999;79: 235–242. 10.1054/tuld.1998.0167 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref018] 18.Kumar NP, Moideen K, Viswanathan V, Sivakumar S, Menon PA, Kornfeld H, et al. Heightened circulating levels of antimicrobial peptides in tuberculosis—Diabetes co-morbidity and reversal upon treatment. PLoS One. 2017;12 10.1371/journal.pone.0184753 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref019] 19.Cheekatla SS, Tripathi D, Venkatasubramanian S, Nathella PK, Paidipally P, Ishibashi M, et al. NK-CD11c+ Cell Crosstalk in Diabetes Enhances IL-6-Mediated Inflammation during Mycobacterium tuberculosis Infection. PLoS Pathog. 2016;12: e1005972 10.1371/journal.ppat.1005972 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref020] 20.Eberl G, Colonna M, Di Santo JP, McKenzie ANJ. Innate Lymphoid Cells: a new paradigm in immunology. Science. 2015;348: aaa6566 10.1126/science.aaa6566 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref021] 21.Vivier E, van de Pavert SA, Cooper MD, Belz GT. The evolution of innate lymphoid cells. Nat Immunol. 2016;17: 790–794. 10.1038/ni.3459 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref022] 22.Ebbo M, Crinier A, Vély F, Vivier E. Innate lymphoid cells: major players in inflammatory diseases. Nature Reviews Immunology. 2017;17: 665–678. 10.1038/nri.2017.86 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref023] 23.Bando JK, Colonna M. Innate lymphoid cell function in the context of adaptive immunity. Nat Immunol. 2016;17: 783–789. 10.1038/ni.3484 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref024] 24.Ardain A, Domingo-Gonzalez R, Das S, Kazer SW, Howard NC, Singh A, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature. 2019;570: 528–532. 10.1038/s41586-019-1276-2 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref025] 25.Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LVM, et al. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol. 2009;183: 6639–6645. 10.4049/jimmunol.0902587 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref026] 26.Ronacher K, Sinha R, Cestari M. IL-22: An Underestimated Player in Natural Resistance to Tuberculosis? Front Immunol. 2018;9 10.3389/fimmu.2018.00009 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref027] 27.Treerat P, Prince O, Cruz-Lagunas A, Muñoz-Torrico M, Salazar-Lezama MA, Selman M, et al. Novel role for IL-22 in protection during chronic Mycobacterium tuberculosis HN878 infection. Mucosal Immunol. 2017;10: 1069–1081. 10.1038/mi.2017.15 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref028] 28.Dhiman R, Periasamy S, Barnes PF, Jaiswal AG, Paidipally P, Barnes AB, et al. NK1. 1+ cells and IL-22 regulate vaccine-induced protective immunity against challenge with Mycobacterium tuberculosis. The Journal of Immunology. 2012;189: 897–905. 10.4049/jimmunol.1102833 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref029] 29.Yi P, Liang Y, Yuan DMK, Jie Z, Kwota Z, Chen Y, et al. A tightly regulated IL-22 response maintains immune functions and homeostasis in systemic viral infection. Scientific Reports. 2017;7: 3857 10.1038/s41598-017-04260-0 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref030] 30.Gimeno Brias S, Stack G, Stacey MA, Redwood AJ, Humphreys IR. The Role of IL-22 in Viral Infections: Paradigms and Paradoxes. Front Immunol. 2016;7 10.3389/fimmu.2016.00007 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref031] 31.Alabbas SY, Begun J, Florin TH, Oancea I. The role of IL‐22 in the resolution of sterile and nonsterile inflammation. Clin Transl Immunology. 2018;7 10.1002/cti2.1017 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref032] 32.Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol. 2011;23: 159–163. 10.1093/intimm/dxr001 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref033] 33.Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol. 2010;107: 1–29. 10.1016/B978-0-12-381300-8.00001-0 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref034] 34.Kumar NP, Banurekha VV, Nair D, Kumaran P, Dolla CK, Babu S. Type 2 diabetes—tuberculosis co-morbidity is associated with diminished circulating levels of IL-20 subfamily of cytokines. Tuberculosis (Edinb). 2015;95: 707–712. 10.1016/j.tube.2015.06.004 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref035] 35.Ronacher K, van Crevel R, Critchley JA, Bremer AA, Schlesinger LS, Kapur A, et al. Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mechanisms. Chest. 2017;152: 174–180. 10.1016/j.chest.2017.02.032 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref036] 36.Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014;514: 237–241. 10.1038/nature13564 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref037] 37.Hasnain SZ, Borg DJ, Harcourt BE, Tong H, Sheng YH, Ng CP, et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med. 2014;20: 1417–1426. 10.1038/nm.3705 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref038] 38.Woting A, Blaut M. Small Intestinal Permeability and Gut-Transit Time Determined with Low and High Molecular Weight Fluorescein Isothiocyanate-Dextrans in C3H Mice. Nutrients. 2018;10 10.3390/nu10060685 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref039] 39.Venkatasubramanian S, Tripathi D, Tucker T, Paidipally P, Cheekatla S, Welch E, et al. Tissue factor expression by myeloid cells contributes to protective immune response against Mycobacterium tuberculosis infection. Eur J Immunol. 2015. 10.1002/eji.201545817 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref040] 40.Fukaya T, Fukui T, Uto T, Takagi H, Nasu J, Miyanaga N, et al. Pivotal Role of IL-22 Binding Protein in the Epithelial Autoregulation of Interleukin-22 Signaling in the Control of Skin Inflammation. Front Immunol. 2018;9 10.3389/fimmu.2018.00009 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref041] 41.Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9: 7204–7218. 10.18632/oncotarget.23208 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref042] 42.Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol. 2008;3: 99–126. 10.1146/annurev.pathmechdis.3.121806.151456 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref043] 43.Robb CT, Regan KH, Dorward DA, Rossi AG. Key mechanisms governing resolution of lung inflammation. Semin Immunopathol. 2016;38: 425–448. 10.1007/s00281-016-0560-6 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref044] 44.McDonough KA, Kress Y. Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infect Immun. 1995;63: 4802–4811. [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref045] 45.Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil Function: From Mechanisms to Disease. Annual Review of Immunology. 2012;30: 459–489. 10.1146/annurev-immunol-020711-074942 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref046] 46.König J, Wells J, Cani PD, García-Ródenas CL, MacDonald T, Mercenier A, et al. Human Intestinal Barrier Function in Health and Disease. Clin Transl Gastroenterol. 2016;7: e196 10.1038/ctg.2016.54 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref047] 47.de Kort S, Keszthelyi D, Masclee A a. M. Leaky gut and diabetes mellitus: what is the link? Obes Rev. 2011;12: 449–458. 10.1111/j.1467-789X.2010.00845.x [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref048] 48.Zhao M, Liao D, Zhao J. Diabetes-induced mechanophysiological changes in the small intestine and colon. World J Diabetes. 2017;8: 249–269. 10.4239/wjd.v8.i6.249 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref049] 49.Valeri M, Raffatellu M. Cytokines IL-17 and IL-22 in the host response to infection. Pathog Dis. 2016;74 10.1093/femspd/ftw111 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref050] 50.Lo BC, Shin SB, Hernaez DC, Refaeli I, Yu HB, Goebeler V, et al. IL-22 Preserves Gut Epithelial Integrity and Promotes Disease Remission during Chronic Salmonella Infection. The Journal of Immunology. 2019; ji1801308 10.4049/jimmunol.1801308 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref051] 51.Zheng C, Hu M, Gao F. Diabetes and pulmonary tuberculosis: a global overview with special focus on the situation in Asian countries with high TB-DM burden. Glob Health Action. 2017;10 10.1080/16549716.2016.1264702 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref052] 52.Berkowitz N, Okorie A, Goliath R, Levitt N, Wilkinson RJ, Oni T. The prevalence and determinants of active tuberculosis among diabetes patients in Cape Town, South Africa, a high HIV/TB burden setting. Diabetes Res Clin Pract. 2018;138: 16–25. 10.1016/j.diabres.2018.01.018 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref053] 53.Leegaard A, Riis A, Kornum JB, Prahl JB, Thomsen VØ, Sørensen HT, et al. Diabetes, Glycemic Control, and Risk of Tuberculosis: A population-based case-control study. Diabetes Care. 2011;34: 2530–2535. 10.2337/dc11-0902 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref054] 54.Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9: 737–746. 10.1016/S1473-3099(09)70282-8 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref055] 55.Kumar NP, Nair D, Banurekha VV, Chandrakumar D, Kumaran P, Sridhar R, et al. Type 2 diabetes mellitus coincident with pulmonary or latent tuberculosis results in modulation of adipocytokines. Cytokine. 2016;79: 74–81. 10.1016/j.cyto.2015.12.026 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref056] 56.Dudakov JA, Hanash AM, van den Brink MRM. Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015;33: 747–785. 10.1146/annurev-immunol-032414-112123 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref057] 57.Bayes HK, Ritchie ND, Ward C, Corris PA, Brodlie M, Evans TJ. IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection. J Cyst Fibros. 2016;15: 759–768. 10.1016/j.jcf.2016.06.008 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref058] 58.Felton JM, Duffin R, Robb CT, Crittenden S, Anderton SM, Howie SEM, et al. Facilitation of IL-22 production from innate lymphoid cells by prostaglandin E2 prevents experimental lung neutrophilic inflammation. Thorax. 2018;73: 1081–1084. 10.1136/thoraxjnl-2017-211097 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref059] 59.Ivanov S, Renneson J, Fontaine J, Barthelemy A, Paget C, Fernandez EM, et al. Interleukin-22 Reduces Lung Inflammation during Influenza A Virus Infection and Protects against Secondary Bacterial Infection. Journal of Virology. 2013;87: 6911–6924. 10.1128/JVI.02943-12 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref060] 60.Andrews C, McLean MH, Durum SK. Cytokine Tuning of Intestinal Epithelial Function. Front Immunol. 2018;9 10.3389/fimmu.2018.00009 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref061] 61.Rendon JL, Li X, Akhtar S, Choudhry MA. IL-22 modulates gut epithelial and immune barrier functions following acute alcohol exposure and burn injury. Shock. 2013;39: 11–18. 10.1097/SHK.0b013e3182749f96 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref062] 62.Lanfranca MP, Lin Y, Fang J, Zou W, Frankel T. Biological and Pathological Activities of Interleukin-22. J Mol Med (Berl). 2016;94: 523–534. 10.1007/s00109-016-1391-6 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref063] 63.Guillon A, Jouan Y, Brea D, Gueugnon F, Dalloneau E, Baranek T, et al. Neutrophil proteases alter the interleukin-22-receptor-dependent lung antimicrobial defence. European Respiratory Journal. 2015;46: 771–782. 10.1183/09031936.00215114 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref064] 64.Li Z, Hodgkinson T, Gothard EJ, Boroumand S, Lamb R, Cummins I, et al. Epidermal Notch1 recruits RORγ⁺ group 3 innate lymphoid cells to orchestrate normal skin repair. Nature Communications. 2016;7: 11394 10.1038/ncomms11394 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref065] 65.Cella M, Miller H, Song C. Beyond NK Cells: The Expanding Universe of Innate Lymphoid Cells. Front Immunol. 2014;5 10.3389/fimmu.2014.00005 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref066] 66.Wang S, Xia P, Chen Y, Qu Y, Xiong Z, Ye B, et al. Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation. Cell. 2017;171: 201–216.e18. 10.1016/j.cell.2017.07.027 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref067] 67.Ouyang W, O’Garra A. IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity. 2019;50: 871–891. 10.1016/j.immuni.2019.03.020 [DOI] [PubMed] [Google Scholar]

[ppat.1008140.ref068] 68.Mühl H, Scheiermann P, Bachmann M, Härdle L, Heinrichs A, Pfeilschifter J. IL-22 in tissue-protective therapy. Br J Pharmacol. 2013;169: 761–771. 10.1111/bph.12196 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref069] 69.Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease. Cellular and Molecular Gastroenterology and Hepatology. 2017;4: 33–46. 10.1016/j.jcmgh.2017.03.007 [DOI] [PMC free article] [PubMed] [Google Scholar]

[ppat.1008140.ref070] 70.Armstrong LE, Lee EC, Armstrong EM. Interactions of Gut Microbiota, Endotoxemia, Immune Function, and Diet in Exertional Heatstroke. In: Journal of Sports Medicine [Internet]. 2018. [cited 28 Mar 2019]. 10.1155/2018/5724575 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

IL-22 produced by type 3 innate lymphoid cells (ILC3s) reduces the mortality of type 2 diabetes mellitus (T2DM) mice infected with Mycobacterium tuberculosis

Deepak Tripathi

Rajesh Kumar Radhakrishnan

Ramya Sivangala Thandi

Padmaja Paidipally

Kamakshi Prudhula Devalraju

Venkata Sanjeev Kumar Neela

Madeline Kay McAllister

Buka Samten

Vijaya Lakshmi Valluri

Ramakrishna Vankayalapati

Roles

Abstract

Author summary

Introduction

Methods

Patient population

Collection of blood sample and plasma separation

Animals

Ethics statement

Induction of type 2 diabetes

Aerosol infection of mice with Mtb H37Rv

Lung cell preparation

Recombinant IL-22 treatment

Isolation of lung epithelial cells

Isolation of type 3 innate lymphoid 3 cells (ILC3s) and adoptive transfer

In vivo intestinal barrier function assay

Antibodies and other reagents

Measurement of serum insulin concentrations

Measurement of serum lipid profiles

Flow cytometry and intracellular staining

Gating strategies

Real-time PCR for the quantification of cytokine mRNA

Histology and immunohistochemistry

Confocal microscopy

Statistical analysis

Results

T2DM inhibits IL-22 production during Mtb infection

Fig 1. T2DM inhibits IL-22 production during Mtb infection.

Type 3 innate lymphoid cells produce IL-22 during Mtb infection

Fig 2. Type 3 innate lymphoid 3 cells (ILC3s) produce IL-22 during Mtb infection.

Recombinant-IL-22 treatment prolongs the survival of Mtb-infected T2DM mice

Fig 3. Recombinant-IL-22 treatment prolongs the survival of Mtb-infected T2DM mice.

Fig 4. IL-22-mediated signaling enhances the gene expression of anti-apoptotic and antimicrobial proteins in lung epithelial cells.

IL-22-producing ILC3s enhance the survival of Mtb-infected T2DM mice

Fig 5. Adoptive transfer of type 3 innate lymphoid cells (ILC3s) enhances the survival of the Mtb-infected T2DM mice.

IL-22 reduces the severity of lung inflammation and neutrophil-mediated damage of lung epithelial cells in Mtb-infected T2DM mice

Fig 6. IL-22 reduces the severity of lung inflammation and neutrophil-mediated damage of lung epithelial cells in Mtb-infected T2DM mice.

IL-22 treatment maintains gut epithelial cell integrity in Mtb-infected T2DM mice

Discussion

Supporting information

Data Availability

Funding Statement

References

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases